HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 01/22/2013 -- Finisar Corporation (NASDAQ:FNSR) stock reported down -10.27% and closed at $13.98 with the total traded volume of 7.32 million shares. Finisar Corporation’s market capitalization is $1.30 billion. The stock owned by insiders was 1.93%. Its price to earnings ratio ended at 65.61 and its earnings per share was $0.21.
How Should Investors React To FNSR Now? Find Out Here
Oi SA (ADR) (NYSE:OIBR) shares fell 1.84% to $4.42 in the previous trading session. The 52 week trading range for the company is $3.62 – $7.04. The shares of the company fell 12% in the last one year. The company is a Brazil-based holding company engaged in the telecommunication sector. The Company is primarily involved in the provision of fixed telephony services in Brazilian states of Acre, Rondonia, Mato Grosso, Mato Grosso do Sul, Tocantins, Goias, Parana, Santa Catarina and Rio Grande do Sul.
Can OIBR Recover After The Recent fall? Find Out Here
Office Depot Inc (NYSE:ODP) remained a bull for the day as it reported the gain of 9.93% and closed at $4.65, after gaining total volume of 15.10 million shares. ODP has the total of 285.23 million outstanding shares and its total market capitalization is $1.33 billion. The Company’s year to date performance remained quite optimistic with the gain of 41.77%, while in the last 6 months, it jumped almost 139.69%. During the last three months, the company reported an upward momentum of 92.95%.
Can ODP Jump Again? Find Out Here
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares fell 6.51% and closed at $9.77. On Jan. 15, some of Arena Pharmaceuticals’ retail-investor shareholders accuse the U.S. Drug Enforcement Agency of conspiring with Wall Street hedge funds to delay the commercial launch of the company’s weight-loss pill Belviq. The DEA is collecting public comments on its proposed rule making Belviq a Schedule IV controlled substance. The 30-day comment period ends on Jan. 18, after which DEA will finalize its ruling.
Can ARNA Bounce Back? Find Out Here
Impax Laboratories Inc (NASDAQ:IPXL) fell 9% to $19.07 in early trading Tuesday morning. The stock is down 25% in the past three months. Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as its drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products.
How Should Investors Trade IPXL Now? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)